Since RCC subtypes have different malignant potential, prognoses and optimal therapies [10], many markers have been tested to support an accurate histological classification, including CD10, RCC marker (RCCma), CK7, CD117, CA9 and AMACR. This evidence concerns the gene MME and renal cell carcinoma.